This article is more than 5 years old. Information may no longer be current.
Iluvien receives reimbursement decree in Italy
Click Here to Manage Email Alerts
Alimera Sciences Limited, a subsidiary of Alimera Sciences Inc., has received a pricing and reimbursement decree for Iluvien in Italy, according to a company press release.
Reimbursement for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) was changed from Class C, in which the patient covers the cost, to Class H, “with a restriction to patients with an artificial lens implanted,” the release said.
“This means that in Italy, Iluvien will be hospital-administered and should be fully reimbursed for those patients who have previously undergone cataract surgery,” the release said.
Iluvien in Europe is used to treat vision impairment associated with chronic diabetic macular edema.
“We now have our first price set in Southern Europe and have a clear path to a new revenue stream with our distributor, Societa Industria Farmaceutica Italiana (SIFI),” Dan Myers, CEO of Alimera, said in the release.